TA-GW immunotherapeutic vaccine: Began a Phase IIa trial in 42 patients using an undisclosed dosing regimen.

Cantab Pharmaceuticals plc (CNTBY), Cambridge, U.K. Product: TA-GW immunotherapeutic vaccine Indication: Treat genital warts Status: Began a Phase IIa trial in 42 patients using an undisclosed dosing ...